Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis.

ABSTRACT:

Introduction

In the advanced stages of chronic kidney disease (CKD), anemia impacts 78.9% to 96.5% of patients. Darbepoetin is utilized for the treatment of anemia associated with chronic kidney disease (CKD). The function of darbepoetin alfa can be clarified by comparing it with other agents. A comprehensive review and network meta-analysis were conducted to assess the safety and efficacy of Darbepoetin alfa compared to other agents in the treatment of anemia associated with chronic kidney disease (CKD).

Methods

A systematic review and network meta-analysis were conducted adhering to PRISMA-NMA guidelines. A systematic search was performed in databases Medline, Embase, and Scopus from inception to November 24, 2024, without language limitations. Randomized controlled trials

SUBMITTER: Hassan MF 

PROVIDER: S-EPMC12625550 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature